Dalton concluded, ‘We are really pleased to possess such a strategic partner as Vista Therapeutics.’.. ActiveCare, Vista Therapeutics announce strategic romantic relationship to build up Nano Biosensors for seniors ActiveCare, Inc. and Vista Therapeutics, Inc. Announced today a strategic relationship to build up Nano Biosensors for ActiveCare’s services and products to be utilized by older people.’ Vista Therapeutics specializes in developing leading nanotechnology. And Harvard University, Vista is advertising and developing nanowire-based biosensors that detect and can take measurements of over 250 indicators or markers. Vista Therapeutics has a number of the world’s foremost scientists in nanotechnologies, including Spencer Farr, PhD, its CEO and Chairman.Cash flow from operations during the quarter was adversely impacted by the payment of $9.1 million of severance charges associated with a workforce decrease, $6.2 million of payments connected with costs incurred related to planned dispositions and $16.7 million of contingent price payments in excess of acquisition day accruals. Additionally, cash flow from functions for the second quarter reflects the payment of $49.6 million of semiannual interest obligations on Senior and Senior Subordinated Notes. Free cash flow for the second one fourth of 2013 was a poor $0.8 million, reflecting cash flow from operations of $27.7 million, offset by capital expenditures of $28.5 million. Non-GAAP EBITDA for the next quarter of 2014 was $110.2 million, which reflects modifications to add back noninterest related restructuring charges of $15.8 million, $0.1 million of acquisition-related costs and $11.6 million of costs associated with potential business dispositions.